Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury. (MSC)
|ClinicalTrials.gov Identifier: NCT01274975|
Recruitment Status : Completed
First Posted : January 12, 2011
Last Update Posted : March 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Spinal Cord Injury||Other: Autologous Adipose Derived Mesenchymal Stem Cells||Phase 1|
Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy.
With the recent demonstration of MSC homing properties, intravenous aplications of MSCs to cell-damaged diseases have increased.
In a human clinical trial, eight male patients who had suffered a spinal cord injury were intravenously administered autologous hAdMSCs (4×10e8 cells) one time.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury|
|Study Start Date :||July 2009|
|Primary Completion Date :||November 2009|
|Study Completion Date :||February 2010|
Other: Autologous Adipose Derived Mesenchymal Stem Cells
- safety evaluation [ Time Frame: 12weeks ]Safety evaluate through physical examination, vital sign and laboratory test after "RNL-Astrostem" injected
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274975
|Principal Investigator:||SangHan Kim, MD||Anyang Sam Hospital|